Compare Microchip Technology Inc. (MCHP) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Natera Inc. Common Stock — how do they compare? Microchip Technology Inc. trades at $70.87 (market cap $40.27B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Microchip Technology Inc. pays a 2.45% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Natera Inc. Common Stock for 0 Days on average.
| MCHP | NTRA | |
|---|---|---|
Market Cap | $40.27B | $57.03B |
Volume | 6,570,711 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $102.97 | $425.64 |
52-Week Low | $49.02 | $179.42 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $45.40B | $56.18B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $71.25, down 3.49% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with strong recent earnings beats but negative net income in 2025. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets. Analyst consensus remains strongly bullish with a $110.50 price target despite current weakness.
MCHP faces near-term headwinds from cyclical semiconductor demand but maintains long-term growth potential through AI infrastructure and automotive connectivity. High valuation ratios (P/E 109.06) and significant debt ($5.63B) present risks, while institutional accumulation and product expansion provide upside catalysts. The stock offers 55% upside to consensus target if execution improves.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
